Cobomarsen, an Oligonucleotide Inhibitor of MiR-155, Slows DLBCL Tumor Cell Growth and
Overview
Authors
Affiliations
Purpose: miRNA-155 is an oncogenic miRNA highly expressed in B-cell malignancies, particularly in the non-germinal center B-cell or activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, we tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in ABC-DLBCL cell lines and in corresponding xenograft mouse models. In addition, we assessed the therapeutic efficacy and safety of cobomarsen in a patient diagnosed with aggressive ABC-DLBCL.
Experimental Design: Preclinical studies included the delivery of cobomarsen to highly miR-155-expressing ABC-DLBCL cell lines to assess any phenotypic changes, as well as intravenous injections of cobomarsen in NSG mice carrying ABC-DLBCL xenografts, to study tumor growth and pharmacodynamics of the compound over time. To begin to test its safety and therapeutic efficacy, a patient was recruited who underwent five cycles of cobomarsen treatment.
Results: Cobomarsen decreased cell proliferation and induced apoptosis in ABC-DLBCL cell lines. Intravenous administration of cobomarsen in a xenograft NSG mouse model of ABC-DLBCL reduced tumor volume, triggered apoptosis, and derepressed direct miR-155 target genes. Finally, the compound reduced and stabilized tumor growth without any toxic effects for the patient.
Conclusions: Our findings support the potential therapeutic application of cobomarsen in ABC-DLBCL and other types of lymphoma with elevated miR-155 expression.
Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.
PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.
The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.
Koumpis E, Georgoulis V, Papathanasiou K, Papoudou-Bai A, Kanavaros P, Kolettas E Biomedicines. 2025; 12(12.
PMID: 39767565 PMC: 11673977. DOI: 10.3390/biomedicines12122658.
The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.
Zhang R, Wang W, Li J, Li R, Zhang J, Wu Y Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200355.
PMID: 39760132 PMC: 11699627. DOI: 10.1016/j.ijcrp.2024.200355.
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.
Hu W, Zang L, Feng X, Zhuang S, Chang L, Liu Y Ann Hematol. 2024; 103(12):5085-5101.
PMID: 39652169 DOI: 10.1007/s00277-024-06131-x.
The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.
Li X, Qian B, Chen X, Shen M, Zhao S, Zhang X Front Immunol. 2024; 15:1464327.
PMID: 39606232 PMC: 11599204. DOI: 10.3389/fimmu.2024.1464327.